Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis
Φόρτωση...
Ημερομηνία
Συγγραφείς
Derdemezis, C. S.
Filippatos, T. D.
Voulgari, P. V.
Tselepis, A. D.
Drosos, A. A.
Kiortsis, D. N.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Fundamental & Clinical Pharmacology
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
Patients with rheumatoid arthritis (RA) appear to have increased plasma levels of leptin and adiponectin. These adipokines may be implicated in the pathophysiology of RA. Tumour necrosis factor alpha (Tau NF-alpha) is a potential modulator of adipokines. The effects of long-term anti-TNF treatment on plasma levels of leptin and adiponectin are not clear. The aim of this study was to assess the effects of 6-month anti-TNF treatment (infliximab) on leptin and adiponectin plasma levels in RA patients. Thirty women with RA were included in the study. Patients with diabetes mellitus, any endocrine disorder or receiving any hypolipidemic or antidiabetic medication were not included. Thirty healthy age- and body mass index-matched women served as controls. Plasma levels of leptin and adiponectin were measured with enzyme immunoassay methods prior to and after the 6-month treatment with infliximab. Mean age and disease duration of patients were 51.8 +/- 14.4 and 12.2 +/- 6.7 years, respectively. Body weight did not change significantly over the 6-month period. Plasma levels of leptin and adiponectin were higher in patients than controls and did not change significantly after 6-month treatment. Interestingly, in the tertile of patients with the highest baseline adiponectin concentrations, adiponectin levels were significantly reduced (P < 0.05). Infliximab treatment did not change plasma levels of leptin and adiponectin after 6-month treatment in the whole study population. However, a reduction of adiponectin levels was observed in patients with higher baseline adiponectin levels.
Περιγραφή
Λέξεις-κλειδιά
adiponectin, anti-tnf, infliximab, leptin, rheumatoid arthritis, antitumor-necrosis-factor, alpha monoclonal-antibody, pulse-wave velocity, tnf-alpha, disease-activity, ankylosing-spondylitis, insulin-resistance, metabolic syndrome, serum-levels, therapy
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
<Go to ISI>://000269577700012
http://onlinelibrary.wiley.com/store/10.1111/j.1472-8206.2009.00717.x/asset/j.1472-8206.2009.00717.x.pdf?v=1&t=h0f7sfo5&s=60eb7c1bdf0627cb54424a7fcfb391f497ea4e22
http://onlinelibrary.wiley.com/store/10.1111/j.1472-8206.2009.00717.x/asset/j.1472-8206.2009.00717.x.pdf?v=1&t=h0f7sfo5&s=60eb7c1bdf0627cb54424a7fcfb391f497ea4e22
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας